CR9444A - Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes - Google Patents
Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantesInfo
- Publication number
- CR9444A CR9444A CR9444A CR9444A CR9444A CR 9444 A CR9444 A CR 9444A CR 9444 A CR9444 A CR 9444A CR 9444 A CR9444 A CR 9444A CR 9444 A CR9444 A CR 9444A
- Authority
- CR
- Costa Rica
- Prior art keywords
- alcohol
- modulars
- relates
- treat
- stimulating substances
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invencion se refiere a metodos y tratamientos para usar composiciones farmaceuticas a partir de una clase de compuestos que modulan selectivamente, directa o indirectamente, la actividad del canal de cloruro GABAA, para tratar el abuso de alcohol y/o substancias estimulantes. La presente invencion tambien se refiere a metodos y protocolos para aliviar los sintomas asociados con el abuso del alcohol y/o substancias estimulantes en un plan de tratamiento compresivo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/111,435 US20050192271A1 (en) | 2003-07-15 | 2005-04-21 | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9444A true CR9444A (es) | 2008-02-20 |
Family
ID=37215204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9444A CR9444A (es) | 2005-04-21 | 2007-10-16 | Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes |
Country Status (17)
Country | Link |
---|---|
US (3) | US20050192271A1 (es) |
EP (1) | EP1742639B1 (es) |
JP (1) | JP2008536921A (es) |
KR (1) | KR20080004615A (es) |
CN (1) | CN101203225A (es) |
AT (1) | ATE539755T1 (es) |
AU (1) | AU2006240324B2 (es) |
BR (1) | BRPI0610038A2 (es) |
CA (1) | CA2605918A1 (es) |
CR (1) | CR9444A (es) |
IL (1) | IL186641A0 (es) |
MX (1) | MX2007012993A (es) |
NO (1) | NO20075562L (es) |
NZ (1) | NZ562585A (es) |
RU (1) | RU2007143053A (es) |
WO (1) | WO2006115743A2 (es) |
ZA (1) | ZA200709048B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
RU2468799C1 (ru) * | 2011-08-03 | 2012-12-10 | Общество с ограниченной ответственностью "Урал Крафт" | Способ купирования алкогольного абстинентного синдрома посредством блокады бензодиазепиновых рецепторов |
EP3057596A4 (en) * | 2013-10-14 | 2017-03-29 | Palmaya Pty Ltd | Compositions and methods of administering same |
US20200143922A1 (en) * | 2016-06-03 | 2020-05-07 | Yale University | Methods and apparatus for predicting depression treatment outcomes |
WO2019195813A1 (en) * | 2018-04-06 | 2019-10-10 | Ovid Therapeutics Inc. | Use of gaboxadol in the treatment of substance use disorders |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5028611A (en) * | 1989-06-29 | 1991-07-02 | The Regents Of The University Of Minnesota | Treatment for cocaine use |
US5519017A (en) * | 1990-03-29 | 1996-05-21 | Lts Lohmann Therapie-Systeme Gmbh + Co. Kg | Pharmaceutic formulation for the treatment of alcoholism |
SE9100860D0 (sv) * | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
DE4123106A1 (de) * | 1991-07-09 | 1993-01-14 | Schering Ag | Arzneimittel zur behandlung von entzugssymptomen |
US5229120A (en) * | 1992-02-05 | 1993-07-20 | Devincent James F | Treatment for cocaine abuse |
US5792796A (en) * | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
GB9420010D0 (en) * | 1994-10-01 | 1994-11-16 | Marck Sharp & Dohme Limited | Nucleic acids |
ATE298747T1 (de) * | 1998-03-31 | 2005-07-15 | Shionogi & Co | Verfahren zur herstellung von 5- hydroxybenzo(b)thiophen-3-carbonsäure |
AU4100699A (en) | 1998-05-28 | 1999-12-13 | Sepracor, Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
US6890951B2 (en) * | 1998-08-05 | 2005-05-10 | Brookhaven Science Associates Llc | Treatment of addiction and addiction-related behavior |
US6541520B1 (en) * | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
US6339106B1 (en) * | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
US6174882B1 (en) * | 1998-11-23 | 2001-01-16 | Sepracor Inc. | 2-hydroxymethylolanzapine compositions and methods |
US6489341B1 (en) * | 1999-06-02 | 2002-12-03 | Sepracor Inc. | Methods for the treatment of neuroleptic and related disorders using sertindole derivatives |
US6399826B1 (en) * | 1999-08-11 | 2002-06-04 | Sepracor Inc. | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
US6750235B1 (en) * | 1999-09-30 | 2004-06-15 | The General Hospital Corporation | Pramipexole as a treatment for cocaine craving |
EP1125579A3 (en) * | 2000-01-18 | 2003-01-02 | Pfizer Products Inc. | Uses of agrp-melanocortin receptor binding modulating compounds |
KR100712570B1 (ko) * | 2001-01-17 | 2007-05-02 | 하이디엄, 인크. | 알콜 의존성 치료약의 제조에서 플루마제닐의 용도 |
US20050192271A1 (en) | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
CN1327843C (zh) * | 2001-02-15 | 2007-07-25 | 海萨姆有限公司 | 氟马西尼在用于可卡因依赖治疗药物制备中的应用 |
US20020150632A1 (en) * | 2001-04-12 | 2002-10-17 | Nick Scott | Psychonutracological method for craving reduction in humans |
FR2827172B1 (fr) * | 2001-07-13 | 2004-07-02 | Pf Medicament | Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides |
US20030176456A1 (en) * | 2001-12-21 | 2003-09-18 | June Harry L. | Methods for reducing alcohol cravings in chronic alcoholics |
US6740677B2 (en) * | 2002-08-19 | 2004-05-25 | Hong Xue | Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids |
DE602004029993D1 (de) * | 2003-02-27 | 2010-12-23 | Eisai R&D Man Co Ltd | Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit |
WO2004110400A2 (en) * | 2003-05-30 | 2004-12-23 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of nalmefene |
JP2005332453A (ja) * | 2004-05-19 | 2005-12-02 | Hitachi Ltd | 情報再生装置及び情報再生方法 |
US20060167723A1 (en) * | 2005-01-21 | 2006-07-27 | Berg L M | Method of treating dependencies |
AU2006235318A1 (en) | 2005-04-07 | 2006-10-19 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
-
2005
- 2005-04-21 US US11/111,435 patent/US20050192271A1/en not_active Abandoned
-
2006
- 2006-04-07 NZ NZ562585A patent/NZ562585A/en not_active IP Right Cessation
- 2006-04-07 MX MX2007012993A patent/MX2007012993A/es not_active Application Discontinuation
- 2006-04-07 EP EP06740763A patent/EP1742639B1/en not_active Not-in-force
- 2006-04-07 JP JP2008507703A patent/JP2008536921A/ja active Pending
- 2006-04-07 WO PCT/US2006/013155 patent/WO2006115743A2/en active Application Filing
- 2006-04-07 KR KR1020077026998A patent/KR20080004615A/ko not_active Application Discontinuation
- 2006-04-07 CA CA002605918A patent/CA2605918A1/en not_active Abandoned
- 2006-04-07 AT AT06740763T patent/ATE539755T1/de active
- 2006-04-07 AU AU2006240324A patent/AU2006240324B2/en not_active Ceased
- 2006-04-07 RU RU2007143053/15A patent/RU2007143053A/ru not_active Application Discontinuation
- 2006-04-07 CN CNA2006800219633A patent/CN101203225A/zh active Pending
- 2006-04-07 BR BRPI0610038A patent/BRPI0610038A2/pt not_active IP Right Cessation
-
2007
- 2007-10-14 IL IL186641A patent/IL186641A0/en unknown
- 2007-10-16 CR CR9444A patent/CR9444A/es not_active Application Discontinuation
- 2007-10-19 ZA ZA200709048A patent/ZA200709048B/xx unknown
- 2007-11-05 NO NO20075562A patent/NO20075562L/no not_active Application Discontinuation
-
2008
- 2008-05-13 US US12/119,911 patent/US7863267B2/en not_active Expired - Lifetime
-
2009
- 2009-03-13 US US12/404,132 patent/US20090215751A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2006115743A2 (en) | 2006-11-02 |
CA2605918A1 (en) | 2006-11-02 |
KR20080004615A (ko) | 2008-01-09 |
IL186641A0 (en) | 2008-06-05 |
US20050192271A1 (en) | 2005-09-01 |
EP1742639B1 (en) | 2012-01-04 |
NZ562585A (en) | 2010-04-30 |
US20090215751A1 (en) | 2009-08-27 |
AU2006240324A1 (en) | 2006-11-02 |
CN101203225A (zh) | 2008-06-18 |
EP1742639A2 (en) | 2007-01-17 |
ZA200709048B (en) | 2008-09-25 |
ATE539755T1 (de) | 2012-01-15 |
US20080207599A1 (en) | 2008-08-28 |
EP1742639A4 (en) | 2008-05-07 |
MX2007012993A (es) | 2008-03-11 |
AU2006240324B2 (en) | 2010-02-25 |
US7863267B2 (en) | 2011-01-04 |
WO2006115743A3 (en) | 2007-06-28 |
JP2008536921A (ja) | 2008-09-11 |
NO20075562L (no) | 2007-12-07 |
RU2007143053A (ru) | 2009-05-27 |
BRPI0610038A2 (pt) | 2016-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20064924L (no) | Eksperimenteringssikker doseringsform som innbefatter an adsorbent og et skadelig middel | |
BRPI0508390B8 (pt) | uso de um anticorpo antagonista anti-ngf, bem como kit e composição farmacêutica para tratamento de dor de câncer de osso | |
BRPI0510043A (pt) | método de tratamento de dor neuropática usando antagonista de receptor crth2 | |
BRPI0908276B8 (pt) | uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite | |
NO20073068L (no) | Stereoisomere anrikete 3-aminokarbonylbisykloheptenpyrimidindiaminforindelser og deres anvendelse | |
EA200700407A1 (ru) | Производные хиназолина и их использования при лечении тромбоцитемии | |
AR083957A1 (es) | Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica | |
EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
ATE554800T1 (de) | Medizinische vorrichtungen mit porösen regionen zur kontrollierten aussetzung oder verabreichung therapeutischer wirkstoffe | |
DE502005010615D1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
PA8637201A1 (es) | Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
CL2007002492A1 (es) | Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras. | |
BRPI0907135B8 (pt) | uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica | |
EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
EA200870089A1 (ru) | Применение производных бензоконденсированного гетероциклического сульфамида для лечения злоупотребления психоактивным веществом и аддикции | |
BRPI0507645A (pt) | anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
ATE350377T1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
ECSP066805A (es) | Compuestos silinano como inhibidores de cisteína proteasa | |
UY30158A1 (es) | Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
CR9444A (es) | Uso de modulares de canal de cloruro selectivos para tratar el abuso de alcohol y/o substancias estimulantes | |
BRPI0511475A (pt) | combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |